Anais Brasileiros de Dermatologia (Aug 2023)

JAK-STAT pathway inhibitors in dermatology

  • Hélio Amante Miot,
  • Paulo Ricardo Criado,
  • Caio César Silva de Castro,
  • Mayra Ianhez,
  • Carolina Talhari,
  • Paulo Müller Ramos

DOI
https://doi.org/10.1016/j.abd.2023.03.001
Journal volume & issue
Vol. 98, no. 5
pp. 656 – 677

Abstract

Read online Read online

Abstract The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main dermatological targets of JAK-STAT pathway inhibitors are inflammatory or autoimmune diseases such as psoriasis, vitiligo, atopic dermatitis and alopecia areata; however, several dermatoses are under investigation to expand this list of indications. As JAK-STAT pathway inhibitors should gradually occupy a relevant space in dermatological prescriptions, this review presents the main available drugs, their immunological effects, and their pharmacological characteristics, related to clinical efficacy and safety, aiming to validate the best dermatological practice.

Keywords